TABLE 2
Selected NRF2 inducers acting as electrophilic modifiers of KEAP1
The reference corresponds to the code in ClinicalTrials.gov.
| Compound | Disease | Clinical Trial | Reference |
|---|---|---|---|
 | Multiple sclerosis | Approved | |
| Psoriasis | Approved | ||
| Rheumatoid arthritis | Phase II | NCT00810836 | |
| Adult brain glioblastoma | Phase I | NCT02337426 | |
| Cutaneous T cell lymphoma | Phase II | NCT02546440 | |
| Obstructive sleep apnea | Phase II | NCT02438137 | |
| Chronic lymphocytic leukemia small lymphocytic lymphoma | Phase I | NCT02784834 | |
 | Multiple sclerosis | Phase III | NCT02634307 |
 | Diabetic nephropathy | Phase II | NCT00811889 |
| Chronic kidney disease, T2DM, diabetic nephropathy | Phase III | NCT01351675 | |
| Liver disease | Phase I/II | NCT00550849 | |
| Hepatic impairment | Phase I | NCT01563562 | |
| Advanced solid tumors Lymphoid malignancies | Phase I | NCT00529438 | |
| NCT00508807 | |||
| Alport syndrome | PhaseII/III | NCT03019185 | |
| Pulmonary hypertension | Phase III | NCT03068130 | |
| Pulmonary arterial hypertension | Phase III | NCT02657356 | |
| Renal insufficiency, T2DM | Phase II | NCT01053936 | |
 | Mitochondrial myopathy | Phase II | NCT02255422 |
| Friedreich’s ataxia | Phase II | NCT02255435 | |
| Inflammation and pain following ocular surgery | Phase II | NCT02065375 | |
| Corneal endothelial cell loss, ocular pain and inflammation, cataract surgery | Phase II | NCT02128113 | |
| Melanoma | Phase I/II | NCT02259231 | |
| Breast cancer | Phase II | NCT02142959 | |
| Non-small cell lung cancer, melanoma | Phase I | NCT02029729 | |
 | Acute kidney injury | Phase I | NCT02248051 |
 | HD | Phase II/III | NCT00277355 |
| Intracerebral hemorrhage | Phase I/II | NCT01805895 | |
| Retinitis pigmentosa | Phase I/II | NCT02140164 | |
| Intracerebral hemorrhage | Phase I/II | NCT03040128 | |
 | NASH | Phase III | NCT02068339 |
| Schistosomiasis | Approved | ||
| Lung cancer | Phase I | NCT00006457 | |
 | Ulcerative colitis | Preclinical PK | —— |
 | Cystic fibrosis | Phase II | NCT01315665 |
| Schizophrenia | Phase II/III | NCT02880462 | |
| Phase II | NCT02810964 | ||
| Phase II | NCT01716858 | ||
| COPD | Phase II | NCT01335971 | |
| Atopic asthmatics | Phase I | NCT01845493 | |
| Autism | Phase II | NCT01474993 | |
| Phase II | NCT02909959 | ||
| Phase II | NCT02677051 | ||
| Phase II | NCT02654743 | ||
| Phase I/II | NCT02561481 | ||
| Healthy | Phase I | NCT01008826 | |
| Phase I | NCT02023931 | ||
| Melanoma | Phase I | NCT01568996 | |
| Asthma | Phase I | NCT01845493 | |
| Phase I/II | NCT01183923 | ||
| Prostate cancer | Phase II | NCT01228084 | |
| Breast cancer | Phase II | NCT00843167 | |
| Lung cancer | Phase II | NCT03232138 | |
| Environmental carcinogenesis | Phase II | NCT01437501 | |
| Alcohol sensitivity | Phase II | NCT01845220 | |
| Aging | Phase II | NCT03126539 | |
| Allergic rhinitis | Phase II | NCT02885025 | |
| Helicobacter pylori infection | Phase IV | NCT03220542 | |
| T2DM | Phase II | NCT02801448 | |
| Head and neck squamous cell carcinoma, head and neck cancer, tobacco-related carcinoma | Phase I | NCT03182959 | |
 | Subarachnoid hemorrhage | Phase II | NCT02614742 |
| Breast neoplasm | Phase I/II | NCT02970682 | |
| Prostate cancer | Phase I | NCT02055716 | |
| NCT01948362 | |||
 | Brain ischemia | Preclinical PK | — |
 | Alzheimer disease | Phase II | NCT02711683 |
| Acute ischemic stroke | Phase I/II | NCT02149875 | |
| Vascular cognitive impairment | Phase II/III | NCT02993367 | |
| Cerebrovascular occlusion, collateral blood circulation, anterior cerebral circulation infarction | Phase IV | NCT02594995 | |
 | Cholestasis | Phase II/III | NCT00846963 |
| HD | Phase I | NCT00514774 | |
| Barrett esophagus, low-grade dysplasia | Phase II | NCT01097304 | |
| Chronic hepatitis C | Phase III | NCT00200343 | |
| T2DM | Phase II | NCT02033876 | |
 | T2DM | Phase I | NCT01677611 |
| Colon cancer | Phase I | NCT00256334 | |
| COPD | Phase III | NCT02245932 | |
| Friedreich ataxia | Phase I/II | NCT01339884 | |
| NASH | Phase II/III | NCT02030977 | |
| Non-ischemic cardiomyopathy | Phase III | NCT01914081 | |
| Endometriosis | Phase IV | NCT02475564 | |
| Chronic renal insufficiency | Phase III | NCT02433925 | |
| Metabolic syndrome X | Phase II | NCT02114892 | |
| Chronic subclinic inflammation | Phase III | NCT01492114 | |
| AD | Phase II | NCT01504854 | |
| Phase III | NCT00743743 | ||
| Colorectal cancer | Phase I | NCT00433576 | |
| HD | Phase III | NCT02336633 | |
 | T2DM, cardiovascular risk | Phase IV | NCT01052025 |
| Schizophrenia, cognition, psychosis | Phase I/II | NCT02104752 | |
| Acute kidney injury, abdominal aortic aneurysm | Phase II/III | NCT01225094 | |
| Chronic kidney diseases, T2DM | Phase II/III | NCT03262363 | |
| AD | Phase I/II | NCT00164749 | |
| Neoplasms | Phase II | NCT02944578 | |
| Crohn's disease | Phase III | NCT02255370 | |
| Chronic schizophrenia | Phase IV | NCT02298985 | |
| Mild cognitive impairment | Phase II | NCT01811381 | |
| Prostate cancer | Phase III | NCT02064673 | |
| Major depression | Phase IV | NCT01750359 | |